Canada's Knight Therapeutics to acquire Biotoscana control by Nov 29-filing

Knight Therapeutics

28/10/2019 23:33

SAO PAULO, Oct 28 (Reuters) - Canada's Knight Therapeutics
Inc  GUD.TO  and shareholders of Biotoscana Investments
 GBIO33.SA  expect to conclude transfer of control of the Latin
American pharmaceutical company by Nov.  29, the latter said in
a securities filing on Monday.
    Knight will spend 596 million reais ($149 million) for 51.2%
of Biotoscana. After the acquisition, the Canadian company will
offer the same price, 10.96 reais per share, to minority
shareholders.
    The total deal value is expected to reach 1.16 billion
reais, or 1.3 billion if Biotoscana's debt is included, the
company added. ($1 = 3.9902 reais)

 (Reporting by Tatiana Bautzer; Editing by Muralikumar
Anantharaman)
 ((tatiana.bautzer@tr.com; Tel: +55-11-5644-7756; Mob:
+55-119-4210-4173; Reuters Messaging:
tatiana.bautzer.thomsonreuters.com@reuters.net))